GZKNCTXA
type: UserItem
resource: Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists
tagged: UserTag
  label: Administration, Oral
tagged: UserTag
  label: Adult
tagged: UserTag
  label: Aged
tagged: UserTag
  label: Aged, 80 and over
tagged: UserTag
  label: Anticoagulants/administration & dosage/*adverse effects
tagged: UserTag
  label: Cohort Studies
tagged: UserTag
  label: Female
tagged: UserTag
  label: Hematuria/*chemically induced/*therapy
tagged: UserTag
  label: Hospitalization/*statistics & numerical data
tagged: UserTag
  label: Humans
tagged: UserTag
  label: Length of Stay/statistics & numerical data
tagged: UserTag
  label: Male
tagged: UserTag
  label: Middle Aged
tagged: UserTag
  label: Retrospective Studies
tagged: UserTag
  label: Vitamin K/*antagonists & inhibitors

Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists
type: AcademicArticle
abstract: OBJECTIVE: To investigate the influence of type of anticoagulation - direct oral anticoagulants (DOAC) vs vitamin K antagonists (VKA) - on length of hospital stay (LOS) and hospitalization rates in patients with visible hematuria, as visible hematuria in anticoagulated patients can be distressing, difficult to control and even life-threatening. METHODS: This retrospective cohort study was conducted at the emergency department (ED) of a tertiary university hospital in Switzerland. All patients admitted with visible hematuria from January 1, 2013 to December 31, 2016 were included. We compared the primary clinical outcome parameters (hospitalization rate and LOS) as well as secondary outcomes (ICU admission, ED LOS, and in-hospital mortality) in patients with visible hematuria on either DOAC therapy, VKA therapy or no anticoagulants. RESULTS: We included 811 (100%) patients with visible hematuria; 53 (6.5%) patients were on DOAC, compared to 85 (10.5%) on VKA and 673 (83.0%) patients without any anticoagulation. In confounder-adjusted multivariable testing, there were fewer hospitalizations (odds ratio: 2.2, 95% confidence interval [CI]: 1.1-4.9, P = .028) and shorter LOS (geometric mean ratio: 2.2, 95% CI: 1.3-4.0, P = .006) on DOAC than on VKA. The secondary outcomes were not significantly associated with the anticoagulation groups. No differences were found between the DOAC and no-anticoagulant groups for any outcome. CONCLUSION: Visible hematuria in patients on DOAC therapy is associated with shorter hospital stays and fewer hospitalizations compared to VKA.
pages: 101-108
doi: 10.1016/j.urology.2019.06.004
source: 31202855
creator: Person
author list: Person
is part of: Issue
  date: 2019-06-17
  volume: 132
  is part of: Urology
    type: Journal
    issn: 1527-9995 (Electronic) 0090-4295 (Linking)

Person
given name: M.
surname: Muller

Person
given name: F.
surname: Bosshard

Person
given name: M.
surname: Nagler

Person
given name: B.
surname: Roth

Person
given name: A. K.
surname: Exadaktylos

Person
given name: T. C.
surname: Sauter